A61K 31/50
Pyridazines
Official title: Pyridazines; Hydrogenated pyridazines
A61K31/50 (Pyridazines) appears on 2,934 US grants and 5,417 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,934
- Published applications
- 5,417
- Assignees
- 1,816
- Inventors
- 12,825
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 8 | 0 |
| 1978 | 2 | 0 |
| 1979 | 4 | 0 |
| 1980 | 0 | 0 |
| 1981 | 4 | 0 |
| 1982 | 3 | 0 |
| 1983 | 3 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 3 | 0 |
| 1987 | 3 | 0 |
| 1988 | 5 | 0 |
| 1989 | 6 | 0 |
| 1990 | 9 | 0 |
| 1991 | 10 | 0 |
| 1992 | 6 | 0 |
| 1993 | 11 | 0 |
| 1994 | 7 | 0 |
| 1995 | 3 | 0 |
| 1996 | 9 | 0 |
| 1997 | 16 | 0 |
| 1998 | 37 | 0 |
| 1999 | 32 | 0 |
| 2000 | 45 | 0 |
| 2001 | 53 | 6 |
| 2002 | 42 | 51 |
| 2003 | 32 | 116 |
| 2004 | 53 | 164 |
| 2005 | 43 | 86 |
| 2006 | 71 | 116 |
| 2007 | 30 | 80 |
| 2008 | 40 | 87 |
| 2009 | 43 | 90 |
| 2010 | 52 | 121 |
| 2011 | 57 | 125 |
| 2012 | 59 | 113 |
| 2013 | 97 | 194 |
| 2014 | 119 | 236 |
| 2015 | 162 | 246 |
| 2016 | 182 | 265 |
| 2017 | 207 | 247 |
| 2018 | 150 | 251 |
| 2019 | 184 | 248 |
| 2020 | 165 | 292 |
| 2021 | 162 | 325 |
| 2022 | 143 | 265 |
| 2023 | 130 | 318 |
| 2024 | 145 | 461 |
| 2025 | 152 | 509 |
| 2026 | 127 | 405 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Dosage forms for TYK2 inhibitors6 Oct 2026US 12,751,948 B2Bristol-Myers Squibb Company
- Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses6 Oct 2026US 12,753,187 B2Merck Sharp & Dohme Corp.
- N2-arylmethyl-4-haloalkyl-pyridazin-3-one CFTR modulators for the treatment of cystic fibrosis29 Sep 2026US 12,747,215 B2Centre National de la Recherche Scientifique (CNRS)
- AP2 associated kinase 1 inhibitors and uses thereof29 Sep 2026US 12,747,245 B2Satellos Bioscience Inc.
- Dosage forms for Tyk2 inhibitors15 Sep 2026US 12,734,169 B2Bristol-Myers Squibb Company
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Pim1 inhibitor for treating myeloproliferative neoplasms8 Oct 2026US 2026/0306490 A1Sumitomo Pharma America, Inc.
- Cis-8-(3,5-Difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives8 Oct 2026US 2026/0308140 A1Gruenenthal GmbH
- Bicyclic heteroarylamides having gpr68 modulating activity8 Oct 2026US 2026/0308159 A1Recursion Pharmaceuticals, Inc.
- Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof1 Oct 2026US 2026/0294884 A1Insilico Medicine IP Limited
Most cited
By later US patents
- In situ photodynamic therapy182US 5,257,970 AHealth Research, Inc. · 1993
- Compositions for treatment of diabetic complications164US 6,069,168 AScotia Holdings PLC · 2000
- Small organic molecule regulators of cell proliferation162US 6,613,798 B1Curis, Inc. · 2003
- Bupropion metabolites and methods of use151US 6,342,496 B12002
- Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction140US 6,037,346 AVivus, Inc. · 2000